Previous Investments1
| Company | Marketer / Counterparty | Description | Initial Investment Date |
|---|---|---|---|
| Vertex | Johnson & Johnson | Telaprevir | October 2009 |
| Royalty Trust | Astellas | Lexiscan | December 2009 |
| CDC | BioDelivery Sciences Ineternational / Meda AB | Onsolis | December 2009 |
| MedPro Safety Products | Greiner Bio-One | Vacuette Safety System | October 2010 |
| Fosamprenavir Royalty, L.P. | ViiV Healthcare / GSK | Lexiva | December 2010 |
| RS Royalty Sub LLC | Pfizer | Lyrica | January 2011 |
| CPEX Pharmaceuticals | Auxilium | Testim | April 2011 |
| Paradigm Spine, LLC | None | coflex | June 2011 |
1. The investments listed in the table include all of Athyrium’s previously recommended investments that meet the criteria of our current mandates and investment strategies.